These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32229347)

  • 21. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
    Guo J; Wang T; Wu T; Zhang K; Yin W; Zhu M; Pang Y; Hao C; He Z; Cheng M; Liu Y; Zheng J; Gu J; Zhao D
    Eur J Med Chem; 2020 Jan; 186():111878. PubMed ID: 31757524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
    Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.
    Chen W; Guo X; Zhang C; Ke D; Zhang G; Yu Y
    Eur J Med Chem; 2019 Dec; 183():111734. PubMed ID: 31569004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
    Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
    Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
    Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
    Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
    Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
    Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors.
    Dadashpour S; Kϋçϋkkılınç TT; Ayazgök B; Hosseinimehr SJ; Chippindale AM; Foroumadi A; Irannejad H
    Future Med Chem; 2019 May; 11(10):1119-1136. PubMed ID: 31280674
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.
    Wierdl M; Tsurkan L; Chi L; Hatfield MJ; Tollemar V; Bradley C; Chen X; Qu C; Potter PM
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):251-263. PubMed ID: 29855693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
    Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
    Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
    Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
    Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.